相似文献
1
Harnessing natural killer T (NKT) cells in human myeloma: progress and challenges.
Clin Immunol. 2011 Aug;140(2):160-6. doi: 10.1016/j.clim.2010.12.010. Epub 2011 Jan 12.
2
Harnessing CD1d-restricted T cells toward antitumor immunity in humans.
Ann N Y Acad Sci. 2009 Sep;1174:61-7. doi: 10.1111/j.1749-6632.2009.04931.x.
3
Defining a novel subset of CD1d-dependent type II natural killer T cells using natural killer cell-associated markers.
Scand J Immunol. 2019 Sep;90(3):e12794. doi: 10.1111/sji.12794. Epub 2019 Jun 26.
4
Acidification-dependent activation of CD1d-restricted natural killer T cells is intact in cystic fibrosis.
Immunology. 2010 Jun;130(2):288-95. doi: 10.1111/j.1365-2567.2009.03234.x. Epub 2010 Jan 19.
5
Application of natural killer T cells in antitumor immunotherapy.
Crit Rev Immunol. 2007;27(6):511-25. doi: 10.1615/critrevimmunol.v27.i6.20.
6
Tumor cells loaded with α-galactosylceramide promote therapeutic NKT-dependent anti-tumor immunity in multiple myeloma.
Immunol Lett. 2013 Nov-Dec;156(1-2):132-9. doi: 10.1016/j.imlet.2013.10.002. Epub 2013 Oct 19.
7
Benzofuran sulfonates and small self-lipid antigens activate type II NKT cells via CD1d.
Proc Natl Acad Sci U S A. 2021 Aug 24;118(34). doi: 10.1073/pnas.2104420118.
8
NKT and tolerance.
Methods Mol Biol. 2011;677:193-206. doi: 10.1007/978-1-60761-869-0_14.
9
Clinical development of a novel CD1d-binding NKT cell ligand as a vaccine adjuvant.
Clin Immunol. 2011 Aug;140(2):142-51. doi: 10.1016/j.clim.2010.11.009. Epub 2010 Dec 24.
10
Human NKT cells express granulysin and exhibit antimycobacterial activity.
J Immunol. 2003 Mar 15;170(6):3154-61. doi: 10.4049/jimmunol.170.6.3154.
引用本文的文献
1
Unraveling Obesity and Multiple Myeloma: Insights from Epidemiology and Molecular Mechanisms.
Curr Obes Rep. 2025 Jun 5;14(1):52. doi: 10.1007/s13679-025-00644-w.
2
Role of Immune Cells and Immunotherapy in Multiple Myeloma.
Life (Basel). 2024 Apr 1;14(4):461. doi: 10.3390/life14040461.
3
Overcoming resistance to programmed cell death protein 1 (PD-1) blockade with allogeneic invariant natural killer T-cells (iNKT).
Oncogene. 2024 Mar;43(10):758-762. doi: 10.1038/s41388-024-02948-y. Epub 2024 Jan 29.
4
Immunomodulation of NK, NKT and B/T cell subtypes in relapsed/refractory multiple myeloma patients treated with pomalidomide along with velcade and dexamethasone and its association with improved progression-free survival.
Front Oncol. 2023 Dec 4;13:1271807. doi: 10.3389/fonc.2023.1271807. eCollection 2023.
5
Obesity as a risk factor for multiple myeloma: insight on the role of adipokines.
Pathol Oncol Res. 2023 Aug 10;29:1611338. doi: 10.3389/pore.2023.1611338. eCollection 2023.
6
Nanobody-derived bispecific CAR-T cell therapy enhances the anti-tumor efficacy of T cell lymphoma treatment.
Mol Ther Oncolytics. 2023 Jul 28;30:86-102. doi: 10.1016/j.omto.2023.07.007. eCollection 2023 Sep 21.
7
Role of Sphingolipids in Multiple Myeloma Progression, Drug Resistance, and Their Potential as Therapeutic Targets.
Front Oncol. 2022 Jun 8;12:925807. doi: 10.3389/fonc.2022.925807. eCollection 2022.
8
Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma.
Nat Cancer. 2020 May;1(5):493-506. doi: 10.1038/s43018-020-0053-3. Epub 2020 Apr 27.
9
Current Progress in CAR-T Cell Therapy for Hematological Malignancies.
J Cancer. 2021 Jan 1;12(2):326-334. doi: 10.7150/jca.48976. eCollection 2021.
10
The Role of Human γδ T Cells in Anti-Tumor Immunity and Their Potential for Cancer Immunotherapy.
Cells. 2020 May 13;9(5):1206. doi: 10.3390/cells9051206.
本文引用的文献
1
Defective NKT cell activation by CD1d+ TRAMP prostate tumor cells is corrected by interleukin-12 with α-galactosylceramide.
PLoS One. 2010 Jun 25;5(6):e11311. doi: 10.1371/journal.pone.0011311.
2
Human leukemic cells loaded with alpha-galactosylceramide (alpha-GalCer) activate murine NKT cells in situ.
Int J Hematol. 2010 Jul;92(1):152-60. doi: 10.1007/s12185-010-0616-7. Epub 2010 Jun 16.
3
Testing the NKT cell hypothesis in lenalidomide-treated myelodysplastic syndrome patients.
Leukemia. 2010 Mar;24(3):592-600. doi: 10.1038/leu.2009.279. Epub 2010 Jan 14.
4
Linking inflammation to natural killer T cell activation.
PLoS Biol. 2009 Oct;7(10):e1000226. doi: 10.1371/journal.pbio.1000226. Epub 2009 Oct 27.
5
Recognition of lyso-phospholipids by human natural killer T lymphocytes.
PLoS Biol. 2009 Oct;7(10):e1000228. doi: 10.1371/journal.pbio.1000228. Epub 2009 Oct 27.
6
Harnessing CD1d-restricted T cells toward antitumor immunity in humans.
Ann N Y Acad Sci. 2009 Sep;1174:61-7. doi: 10.1111/j.1749-6632.2009.04931.x.
7
Kinetics and cellular site of glycolipid loading control the outcome of natural killer T cell activation.
Immunity. 2009 Jun 19;30(6):888-98. doi: 10.1016/j.immuni.2009.03.022.
8
Determination of cellular lipids bound to human CD1d molecules.
PLoS One. 2009;4(5):e5325. doi: 10.1371/journal.pone.0005325. Epub 2009 May 5.
9
Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages.
J Clin Invest. 2009 Jun;119(6):1524-36. doi: 10.1172/JCI37869.
10
Natural lipid ligands associated with human CD1d targeted to different subcellular compartments.
J Immunol. 2009 Apr 15;182(8):4784-91. doi: 10.4049/jimmunol.0803981.
Zotero 插件